This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Common Warts Market

Market Insights on Common Warts covering sales outlook, demand forecast & up-to-date key trends

Common Warts Market by Diagnosis Procedure, Drug Type, Medication Class & Region – Forecast 2023–2033

Common Warts Market Snapshot (2023-2033)

The global common warts market garnered a market value of US $ 770 Million in 2023 and is expected to accumulate a market value of US$ 1100 Million by registering a CAGR of 3.6% in the forecast period 2023-2033. The worldwide common warts market was extremely strong in 2021 and is predicted to exhibit quick revenue CAGR during the forecast period. Immunosuppression is a substantial risk factor for persistent infections with Human Papilloma Viruses (HPV) and HPV-associated illness, with a frequency of 10% to 20% among school-aged children.

During the COVID pandemic, the number of immunocompromised people grew, leading to market expansion. However, the worldwide common warts market might be limited by high treatment prices and a lack of treatment availability. During the projected period, factors such as the expanding geriatric population are likely to fuel market revenue growth. The growing number of people being diagnosed with warts, owing to developments in diagnostics and HPV infections, is a key driver driving market expansion.

According to the Centers for Disease Control and Prevention, 340,000 to 360,000 people are affected by HPV-related genital warts each year. In the United States, approximately one in every 100 sexually active persons has genital warts at any one time. Moreover, the increasing frequency of warts in the general population is expected to increase the market for common warts. Furthermore, the market is expanding as a result of a rise in scientific trials conducted by various pharmaceutical companies and increased need for specific therapy to address various issues caused by common warts. These are the variables that are driving the common warts market forward.

Data Points

Key Statistics

Expected Market Value (2023)

US$ 770 Million

Anticipated Forecast Value (2033)

US$ 1,100 Million

Projected Growth Rate (2023-2033)

3.6% CAGR

Customize this Report

Let us know your requirement to get
100% FREE customization

Common Warts Demand Analysis (2017 to 2022) Vs Market Outlook (2023 to 2033)

The global demand for common warts is projected to increase at a CAGR of 3.6% during the forecast period between 2022 and 2032, reaching a total of US$ 1,100 Million in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2022, sales witnessed significant growth, registering a CAGR of 2%.

The recurrence rate of genital warts treated with topical podophyllotoxin therapy ranges between 6% and 100%. According to the Centers for Disease Control and Prevention (CDC), anogenital warts often reoccur within three months. Thus, when the recurrence incidence of warts increases, so does the use of goods and therapy, driving the market for common warts.

HPV viruses promote excessive and fast development of keratin, a hard protein found on the skin's top layer. According to the Anal Cancer Foundation, an estimated 14 million people in the United States are infected with HPV each year. According to the Centers for Disease Control and Prevention (CDC), genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the United States each year. As a result, an increase in the prevalence of warts and HPV infections supports the expansion of the common warts market.

Which are Some Prominent Drivers of Common Warts Market?

The Increasing Prevalence of Common Warts and HPV infections is propelling Market Growth

People with weaker immune systems as a result of organ transplants, major illnesses such as cancer or AIDS, and atopic disorders are more likely to get warts. As a result, an increase in the number of cancer patients raises the prevalence of warts, driving the common warts market.

An increase in the number of HPV infections increases the danger of warts and, as a result, the market. According to the Anal Cancer Foundation, an estimated 14 million people in the United States are infected with HPV each year. According to the Centers for Disease Control and Prevention, genital warts caused by HPV afflict around 340,000 to 360,000 women and men in the United States each year, and they normally appear 2 to 3 months after HPV infection.

There are several treatments available for warts, but recurrences are common. A large majority of instances of genital warts do not respond to therapy and frequently reoccur, especially when infections from HPV have a protracted incubation period. As a result, an increase in the recurrence rate of common warts increases the need of products and therapy. This, in turn, is projected to fuel the market for common warts.

Sabyasachi Ghosh
Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which are the Trough Areas faced by the Common Warts Market?

The Common Warts Market is being Hampered by a Low Diagnostic Rate due to a Lack of Awareness

The expansion of the worldwide common warts market is anticipated to be impeded by a lack of knowledge of the diagnosis, which results in fewer reported instances and, as a result, less relevance for treatment choices. Although the frequency of warts is increased, the diagnostic rate in patients is low.

For example, according to the 2018 Health Protection Report, the prevalence of genital warts diagnosis among girls aged 15 to 17 in England accessing sexual health services reduced by 92% compared to 2014.

Region-Wise Insights

How will Common Warts Market Demand progress in the Asia Pacific?

Government Support to Raise Awareness about Sexually Transmitted Diseases Widening Profit Margins

Over the projection period, Asia Pacific is predicted to have high revenue CAGR. There is a significant growth in the elderly population in nations such as China, India, and others.

Moreover, the region's development rate will be enhanced due to the presence of generic producers and the expansion of healthcare facilities. These important drivers are projected to fuel market revenue growth throughout the forecast period.

Furthermore, the government support to raise awareness about sexually transmitted diseases, an increase in demand for advanced therapeutics, an increase in the prevalence of HPV infections, a rising economy, and a shift in sexual lifestyles in the area are key drivers of the Asia Pacific common warts market. As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023-2033.

How attractive are Growth Prospects for Common Warts in North America?

Increase in Pharmaceutical Firms' R&D Efforts to Accelerate Market Growth

The development of the North American market is attributable to an increase in pharmaceutical firms' R&D efforts, a high rate of treatment acceptance in healthcare facilities, and a rise in knowledge about the impacts of common warts. North America is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.

MarketNage
Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Category-Wise Insights

Which Drug Type is expected to Remain Highly Sought After?

Because of Its Low Cost, Salicylic Acid Improves Clinical Outcomes

There is a growing desire for common warts therapy that leaves no scars and gives lifetime protection against HPV. As a result, businesses in the common warts market are focusing more on tissue keratolysis in order to improve patient results.

Tissue keratolysis, which uses salicylic acid, is popular in over-the-counter (OTC) drugs. This is clear since salicylic acid, a chemical destruction therapy option, is predicted to increase at an exponential rate in the common warts market throughout the projection period.

Market Competition

Key players in the common warts market are Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd.

Recent Developments

  • In April 2020, Orgenesis Inc. acquired Tamir Biotechnology, Inc., including Ranpirnase, Tamir Bio's broad spectrum antiviral platform. Total stock and cash consideration was about USD 21 million based on stock valuation at the time of close.

Report Scope

Report Attribute

Details

Market Value in 2023

US$ 770 Million

Market Value in 2033

US$ 1,100 Million

Growth Rate

CAGR of 3.6% from 2023 to 2033

Base Year for Estimation

2022

Historical Data

2018-2022

Forecast Period

2023-2033

Quantitative Units

Revenue in US$ Billion and CAGR from 2023-2033

Report Coverage

Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis

Segments Covered

  • Diagnosis Procedure
  • Drug Type
  • Medication Class
  • Region

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Countries Profiled

  • U.S
  • Canada
  • Brazil
  • Mexico
  • Germany
  • U.K
  • France
  • Spain
  • Italy
  • China
  • Japan
  • South Korea
  • Singapore
  • Thailand
  • Indonesia
  • Australia
  • New Zealand
  • GCC
  • South Africa
  • Israel

Key Companies Profiled

  • Nielsen BioSciences
  • Verrica Pharmaceutical
  • Aclaris Therapeutics, Inc.
  • KinoPharma, Inc.
  • pHion Therapeutics
  • Orgenesis
  • Novan
  • Cassopeia Pharmaceuticals
  • Innovax

Customization

Available Upon Request

Key Segments Profiled in the Common Warts Market Industry Survey

Common Warts Market by Diagnosis:

  • Biopsy
  • Excision

Common Warts Market by Drug Type:

  • Imiquimod
  • Silver Nitrate
  • Glutaraldehyde
  • Salicylic Acid
  • Formaldehydel
  • Aminolevulinic Acid

Common Warts Market by Medication Class:

  • Topical Retinoids
  • Oral Retinoids

Common Warts Market by Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Frequently Asked Questions

FMI projects the global common warts market to expand at a 3.6% value CAGR by 2033

The global common warts market is estimated at a market value of US$ 770 Million

The global market for common warts treatment is expected to garner a market value of US$ 1100 Million

As per Future Market Insights, the Asia Pacific is expected to grow at a CAGR of 3% in the assessment period 2023-2033.

Nielsen BioSciences, Verrica Pharmaceutical, Aclaris Therapeutics, Inc., KinoPharma, Inc., pHion Therapeutics, Orgenesis, Novan, Cassopeia Pharmaceuticals, Innovax and Torii Pharmaceutical Co. Ltd., are some prominent Common Warts manufacturers

North America is expected to grow at a CAGR of 3.5% in the assessment period 2023-2033.

Europe is expected to grow at a CAGR of 3.3% in the assessment period 2023-2033.

The Salicylic Acid segment is expected to hold the largest market share for common warts in the forecast period 2023-2033.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018-2022 and Forecast, 2023-2033

    4.1. Historical Market Size Value (US$ Mn) Analysis, 2018-2022

    4.2. Current and Future Market Size Value (US$ Mn) Projections, 2023-2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Diagnosis Procedure

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Mn) Analysis By Diagnosis Procedure, 2018-2022

    5.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Diagnosis Procedure, 2023-2033

        5.3.1. Biopsy

        5.3.2. Excision

    5.4. Y-o-Y Growth Trend Analysis By Diagnosis Procedure, 2018-2022

    5.5. Absolute $ Opportunity Analysis By Diagnosis Procedure, 2023-2033

6. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Drug Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Mn) Analysis By Drug Type, 2018-2022

    6.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Drug Type, 2023-2033

        6.3.1. Imiquimod

        6.3.2. Silver Nitrate

        6.3.3. Glutaraldehyde

        6.3.4. Salicylic Acid

        6.3.5. Formaldehyde

        6.3.6. Aminolevulinic Acid

    6.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018-2022

    6.5. Absolute $ Opportunity Analysis By Drug Type, 2023-2033

7. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Medication Class

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Mn) Analysis By Medication Class , 2018-2022

    7.3. Current and Future Market Size Value (US$ Mn) Analysis and Forecast By Medication Class , 2023-2033

        7.3.1. Topical Retinoids

        7.3.2. Oral Retinoids

    7.4. Y-o-Y Growth Trend Analysis By Medication Class , 2018-2022

    7.5. Absolute $ Opportunity Analysis By Medication Class , 2023-2033

8. Global Market Analysis 2018-2022 and Forecast 2023-2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Mn) Analysis By Region, 2018-2022

    8.3. Current Market Size Value (US$ Mn) Analysis and Forecast By Region, 2023-2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. Asia Pacific

        8.3.5. MEA

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    9.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    9.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        9.2.1. By Country

            9.2.1.1. U.S.

            9.2.1.2. Canada

        9.2.2. By Diagnosis Procedure

        9.2.3. By Drug Type

        9.2.4. By Medication Class

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Diagnosis Procedure

        9.3.3. By Drug Type

        9.3.4. By Medication Class

    9.4. Key Takeaways

10. Latin America Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    10.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    10.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Diagnosis Procedure

        10.2.3. By Drug Type

        10.2.4. By Medication Class

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Diagnosis Procedure

        10.3.3. By Drug Type

        10.3.4. By Medication Class

    10.4. Key Takeaways

11. Europe Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    11.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    11.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. U.K.

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Diagnosis Procedure

        11.2.3. By Drug Type

        11.2.4. By Medication Class

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Diagnosis Procedure

        11.3.3. By Drug Type

        11.3.4. By Medication Class

    11.4. Key Takeaways

12. Asia Pacific Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    12.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    12.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

            12.2.1.4. Singapore

            12.2.1.5. Thailand

            12.2.1.6. Indonesia

            12.2.1.7. Australia

            12.2.1.8. New Zealand

            12.2.1.9. Rest of Asia Pacific

        12.2.2. By Diagnosis Procedure

        12.2.3. By Drug Type

        12.2.4. By Medication Class

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Diagnosis Procedure

        12.3.3. By Drug Type

        12.3.4. By Medication Class

    12.4. Key Takeaways

13. MEA Market Analysis 2018-2022 and Forecast 2023-2033, By Country

    13.1. Historical Market Size Value (US$ Mn) Trend Analysis By Market Taxonomy, 2018-2022

    13.2. Market Size Value (US$ Mn) Forecast By Market Taxonomy, 2023-2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Diagnosis Procedure

        13.2.3. By Drug Type

        13.2.4. By Medication Class

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Diagnosis Procedure

        13.3.3. By Drug Type

        13.3.4. By Medication Class

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. U.S.

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Diagnosis Procedure

            14.1.2.2. By Drug Type

            14.1.2.3. By Medication Class

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Diagnosis Procedure

            14.2.2.2. By Drug Type

            14.2.2.3. By Medication Class

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Diagnosis Procedure

            14.3.2.2. By Drug Type

            14.3.2.3. By Medication Class

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Diagnosis Procedure

            14.4.2.2. By Drug Type

            14.4.2.3. By Medication Class

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Diagnosis Procedure

            14.5.2.2. By Drug Type

            14.5.2.3. By Medication Class

    14.6. U.K.

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Diagnosis Procedure

            14.6.2.2. By Drug Type

            14.6.2.3. By Medication Class

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Diagnosis Procedure

            14.7.2.2. By Drug Type

            14.7.2.3. By Medication Class

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Diagnosis Procedure

            14.8.2.2. By Drug Type

            14.8.2.3. By Medication Class

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Diagnosis Procedure

            14.9.2.2. By Drug Type

            14.9.2.3. By Medication Class

    14.10. China

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Diagnosis Procedure

            14.10.2.2. By Drug Type

            14.10.2.3. By Medication Class

    14.11. Japan

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Diagnosis Procedure

            14.11.2.2. By Drug Type

            14.11.2.3. By Medication Class

    14.12. South Korea

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Diagnosis Procedure

            14.12.2.2. By Drug Type

            14.12.2.3. By Medication Class

    14.13. Singapore

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Diagnosis Procedure

            14.13.2.2. By Drug Type

            14.13.2.3. By Medication Class

    14.14. Thailand

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Diagnosis Procedure

            14.14.2.2. By Drug Type

            14.14.2.3. By Medication Class

    14.15. Indonesia

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Diagnosis Procedure

            14.15.2.2. By Drug Type

            14.15.2.3. By Medication Class

    14.16. Australia

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Diagnosis Procedure

            14.16.2.2. By Drug Type

            14.16.2.3. By Medication Class

    14.17. New Zealand

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Diagnosis Procedure

            14.17.2.2. By Drug Type

            14.17.2.3. By Medication Class

    14.18. GCC Countries

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Diagnosis Procedure

            14.18.2.2. By Drug Type

            14.18.2.3. By Medication Class

    14.19. South Africa

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Diagnosis Procedure

            14.19.2.2. By Drug Type

            14.19.2.3. By Medication Class

    14.20. Israel

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Diagnosis Procedure

            14.20.2.2. By Drug Type

            14.20.2.3. By Medication Class

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Diagnosis Procedure

        15.3.3. By Drug Type

        15.3.4. By Medication Class

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Nielsen BioSciences

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Verrica Pharmaceutical

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Aclaris Therapeutics, Inc.

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. KinoPharma, Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. pHion Therapeutics

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Orgenesis

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Novan

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. Cassopeia Pharmaceuticals

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Innovax

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Torii Pharmaceutical Co. Ltd.

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 1: Global Market Value (US$ Mn) Forecast by Region, 2018-2033

Table 2: Global Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033

Table 3: Global Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 4: Global Market Value (US$ Mn) Forecast by Medication Class , 2018-2033

Table 5: North America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 6: North America Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033

Table 7: North America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 8: North America Market Value (US$ Mn) Forecast by Medication Class , 2018-2033

Table 9: Latin America Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 10: Latin America Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033

Table 11: Latin America Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 12: Latin America Market Value (US$ Mn) Forecast by Medication Class , 2018-2033

Table 13: Europe Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 14: Europe Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033

Table 15: Europe Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 16: Europe Market Value (US$ Mn) Forecast by Medication Class , 2018-2033

Table 17: Asia Pacific Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 18: Asia Pacific Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033

Table 19: Asia Pacific Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 20: Asia Pacific Market Value (US$ Mn) Forecast by Medication Class , 2018-2033

Table 21: MEA Market Value (US$ Mn) Forecast by Country, 2018-2033

Table 22: MEA Market Value (US$ Mn) Forecast by Diagnosis Procedure, 2018-2033

Table 23: MEA Market Value (US$ Mn) Forecast by Drug Type, 2018-2033

Table 24: MEA Market Value (US$ Mn) Forecast by Medication Class , 2018-2033

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033

Figure 2: Global Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 3: Global Market Value (US$ Mn) by Medication Class , 2023-2033

Figure 4: Global Market Value (US$ Mn) by Region, 2023-2033

Figure 5: Global Market Value (US$ Mn) Analysis by Region, 2018-2033

Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023-2033

Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023-2033

Figure 8: Global Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033

Figure 9: Global Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033

Figure 10: Global Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033

Figure 11: Global Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 12: Global Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 13: Global Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 14: Global Market Value (US$ Mn) Analysis by Medication Class , 2018-2033

Figure 15: Global Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033

Figure 16: Global Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033

Figure 17: Global Market Attractiveness by Diagnosis Procedure, 2023-2033

Figure 18: Global Market Attractiveness by Drug Type, 2023-2033

Figure 19: Global Market Attractiveness by Medication Class , 2023-2033

Figure 20: Global Market Attractiveness by Region, 2023-2033

Figure 21: North America Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033

Figure 22: North America Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 23: North America Market Value (US$ Mn) by Medication Class , 2023-2033

Figure 24: North America Market Value (US$ Mn) by Country, 2023-2033

Figure 25: North America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 28: North America Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033

Figure 29: North America Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033

Figure 30: North America Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033

Figure 31: North America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 32: North America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 33: North America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 34: North America Market Value (US$ Mn) Analysis by Medication Class , 2018-2033

Figure 35: North America Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033

Figure 36: North America Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033

Figure 37: North America Market Attractiveness by Diagnosis Procedure, 2023-2033

Figure 38: North America Market Attractiveness by Drug Type, 2023-2033

Figure 39: North America Market Attractiveness by Medication Class , 2023-2033

Figure 40: North America Market Attractiveness by Country, 2023-2033

Figure 41: Latin America Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033

Figure 42: Latin America Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 43: Latin America Market Value (US$ Mn) by Medication Class , 2023-2033

Figure 44: Latin America Market Value (US$ Mn) by Country, 2023-2033

Figure 45: Latin America Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 48: Latin America Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033

Figure 49: Latin America Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033

Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033

Figure 51: Latin America Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 52: Latin America Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 54: Latin America Market Value (US$ Mn) Analysis by Medication Class , 2018-2033

Figure 55: Latin America Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033

Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033

Figure 57: Latin America Market Attractiveness by Diagnosis Procedure, 2023-2033

Figure 58: Latin America Market Attractiveness by Drug Type, 2023-2033

Figure 59: Latin America Market Attractiveness by Medication Class , 2023-2033

Figure 60: Latin America Market Attractiveness by Country, 2023-2033

Figure 61: Europe Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033

Figure 62: Europe Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 63: Europe Market Value (US$ Mn) by Medication Class , 2023-2033

Figure 64: Europe Market Value (US$ Mn) by Country, 2023-2033

Figure 65: Europe Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 68: Europe Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033

Figure 69: Europe Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033

Figure 70: Europe Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033

Figure 71: Europe Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 72: Europe Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 73: Europe Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 74: Europe Market Value (US$ Mn) Analysis by Medication Class , 2018-2033

Figure 75: Europe Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033

Figure 76: Europe Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033

Figure 77: Europe Market Attractiveness by Diagnosis Procedure, 2023-2033

Figure 78: Europe Market Attractiveness by Drug Type, 2023-2033

Figure 79: Europe Market Attractiveness by Medication Class , 2023-2033

Figure 80: Europe Market Attractiveness by Country, 2023-2033

Figure 81: Asia Pacific Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033

Figure 82: Asia Pacific Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 83: Asia Pacific Market Value (US$ Mn) by Medication Class , 2023-2033

Figure 84: Asia Pacific Market Value (US$ Mn) by Country, 2023-2033

Figure 85: Asia Pacific Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 86: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 87: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 88: Asia Pacific Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033

Figure 89: Asia Pacific Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033

Figure 90: Asia Pacific Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033

Figure 91: Asia Pacific Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 92: Asia Pacific Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 93: Asia Pacific Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 94: Asia Pacific Market Value (US$ Mn) Analysis by Medication Class , 2018-2033

Figure 95: Asia Pacific Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033

Figure 96: Asia Pacific Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033

Figure 97: Asia Pacific Market Attractiveness by Diagnosis Procedure, 2023-2033

Figure 98: Asia Pacific Market Attractiveness by Drug Type, 2023-2033

Figure 99: Asia Pacific Market Attractiveness by Medication Class , 2023-2033

Figure 100: Asia Pacific Market Attractiveness by Country, 2023-2033

Figure 101: MEA Market Value (US$ Mn) by Diagnosis Procedure, 2023-2033

Figure 102: MEA Market Value (US$ Mn) by Drug Type, 2023-2033

Figure 103: MEA Market Value (US$ Mn) by Medication Class , 2023-2033

Figure 104: MEA Market Value (US$ Mn) by Country, 2023-2033

Figure 105: MEA Market Value (US$ Mn) Analysis by Country, 2018-2033

Figure 106: MEA Market Value Share (%) and BPS Analysis by Country, 2023-2033

Figure 107: MEA Market Y-o-Y Growth (%) Projections by Country, 2023-2033

Figure 108: MEA Market Value (US$ Mn) Analysis by Diagnosis Procedure, 2018-2033

Figure 109: MEA Market Value Share (%) and BPS Analysis by Diagnosis Procedure, 2023-2033

Figure 110: MEA Market Y-o-Y Growth (%) Projections by Diagnosis Procedure, 2023-2033

Figure 111: MEA Market Value (US$ Mn) Analysis by Drug Type, 2018-2033

Figure 112: MEA Market Value Share (%) and BPS Analysis by Drug Type, 2023-2033

Figure 113: MEA Market Y-o-Y Growth (%) Projections by Drug Type, 2023-2033

Figure 114: MEA Market Value (US$ Mn) Analysis by Medication Class , 2018-2033

Figure 115: MEA Market Value Share (%) and BPS Analysis by Medication Class , 2023-2033

Figure 116: MEA Market Y-o-Y Growth (%) Projections by Medication Class , 2023-2033

Figure 117: MEA Market Attractiveness by Diagnosis Procedure, 2023-2033

Figure 118: MEA Market Attractiveness by Drug Type, 2023-2033

Figure 119: MEA Market Attractiveness by Medication Class , 2023-2033

Figure 120: MEA Market Attractiveness by Country, 2023-2033

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Epidermal Nevus Syndrome Market

Published : April 2020

Healthcare

Skin Grafting System Market

Published : August 2016

Healthcare

Scabies Treatment Market

Published : April 2016

Healthcare

Skin Replacement Market

Published : February 2022

Google translate